Fortress Biotech, Inc.
FBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001429260
In the last 90 days, Fortress Biotech, Inc. insiders filed 2 open-market purchases and 0 sales; 59 institutions reported holding it in 13F filings for Q3 2026, worth $17.7M in total; no superinvestor holds it.
Other share classesFBIOP
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:24 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net income for FY2025: $6.82M (10.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 28, 2022 |
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Cost of revenue | $20.9M | $20.9M | $26.7M | $30.8M | $32.1M |
| Research and development | $11.9M | $56.6M | $106.1M | $134.9M | $128.9M |
| Selling, general and administrative | $96.4M | $87.7M | $94.1M | $113.7M | $86.8M |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M |
| Interest expense | $10.1M | $13.5M | $15.3M | $12.5M | $15.3M |
| Income tax | -$620.0K | $312.0K | $521.0K | $449.0K | $473.0K |
| Net income | $6.82M | -$46.0M | -$60.6M | -$86.6M | -$64.7M |
| EPS, basic | $-0.07 | $-2.69 | $-8.47 | $-0.97 | – |
| EPS, diluted | $-0.07 | $-2.69 | $-8.47 | $-0.97 | – |
| Weighted shares, basic | 27.9M | 20.8M | 8.11M | 88.9M | – |
| Weighted shares, diluted | 27.9M | 20.8M | 8.11M | 88.9M | – |
| Margins and growth | |||||
| Operating margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% |
| Net margin | 10.8% | -79.8% | -71.7% | -114.3% | -94.1% |
| Revenue growth, year over year | +9.7% | −31.8% | +11.6% | +10.1% | +50.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 28, 2022 |
| Cash and equivalents | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
| Accounts receivable | $29.8M | $10.2M | $15.2M | $28.2M | $23.1M |
| Inventory | $9.62M | $14.4M | $10.2M | $14.2M | $9.86M |
| Total current assets | $123.8M | $90.4M | $117.0M | $230.4M | $346.5M |
| Property, plant and equipment | $2.52M | $3.26M | $6.50M | $13.0M | $15.1M |
| Intangible assets | $27.6M | $31.9M | $20.3M | $27.2M | $12.6M |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M |
| Accounts payable | $14.2M | $31.6M | $34.8M | $57.2M | $47.4M |
| Total current liabilities | $49.7M | $71.4M | $84.9M | $127.7M | $101.0M |
| Long-term debt | $52.4M | $58.0M | $60.9M | $91.7M | $42.9M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Shareholders' equity | $62.2M | -$1.64M | $1.59M | $50.0M | $225.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 28, 2022 |
| Operating cash flow | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M |
| Capital expenditures | – | $0 | $63.0K | $2.71M | $4.57M |
| Free cash flow | – | -$80.2M | -$128.3M | -$182.1M | -$121.1M |
| Stock-based compensation | $28.7M | $32.6M | $17.0M | $23.0M | $19.5M |
| Dividends paid | $664.0K | $694.0K | $736.0K | $749.0K | $749.0K |
| Investing cash flow | $10.1M | -$15.0M | -$2.10M | -$22.9M | $40.5M |
| Financing cash flow | $77.4M | $70.6M | $32.7M | $75.3M | $149.0M |
| Net change in cash | $21.8M | -$24.6M | -$97.6M | -$127.0M | $73.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 45.4% | 56.6% | 20.1% | 30.3% | 28.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| May 7, 2020 | 82.5M | +26.4% | SEC |
| Mar 12, 2020 | 78.5M | +28.0% | SEC |
| Nov 8, 2019 | 70.8M | +24.9% | SEC |
| Aug 6, 2019 | 69.0M | +27.1% | SEC |
| May 8, 2019 | 65.2M | +23.3% | SEC |
| Mar 14, 2019 | 61.3M | +19.4% | SEC |
| Nov 7, 2018 | 56.7M | +11.9% | SEC |
| Aug 9, 2018 | 54.3M | +7.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q4 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.